Form 4: Guardant Health CPO Reports Stock Transactions

Guardant Health's Chief People Officer, Terilyn J. Monroe, reported the vesting of restricted stock units and related tax-driven share disposals.

Summary

• Terilyn J. Monroe, Chief People Officer of Guardant Health, Inc., reported transactions involving the company's common stock.
• On January 1, 2026, Monroe acquired 14,896 shares of common stock through the vesting of performance-based restricted stock units (RSUs) at a price of $0.
• Also on January 1, 2026, an additional 2,659 shares of common stock were acquired through the vesting of standard restricted stock units at a price of $0.
• To cover tax withholding obligations related to the RSU vesting, 7,524 shares of common stock were disposed of at a price of $102.14 per share on January 1, 2026.
• Monroe also acquired 70 shares under Guardant Health's Employee Stock Purchase Plan on November 14, 2025.
• Following these transactions, Monroe beneficially owns 31,021 shares of common stock directly.
• Remaining derivative holdings include 14,898 performance-based restricted stock units and 18,615 restricted stock units.

Sentiment

Score: 5

Explanation: The filing reports routine insider transactions related to equity compensation vesting and tax withholding, which are neutral events. The achievement of performance metrics for RSU vesting is a minor positive.

Positives

• The vesting of performance-based restricted stock units indicates that a performance metric was achieved, reflecting positively on company or individual performance.
• Continued insider ownership and participation in the Employee Stock Purchase Plan demonstrate alignment of management interests with shareholders.

Negatives

• Disposal of shares for tax withholding is a routine event and does not necessarily indicate a negative outlook.

Future Outlook

The filing indicates future vesting events for restricted stock units, with 34% of performance-based RSUs scheduled to vest on January 1, 2027, and the remaining 67% of standard RSUs vesting in equal quarterly installments over a two-year period following October 1, 2025.

Industry Context

This Form 4 filing details routine insider stock transactions, specifically the vesting of equity awards and subsequent tax-related share disposals, which are common occurrences for executives in publicly traded companies within the biotechnology and healthcare diagnostics sector. Such filings provide transparency into executive compensation and ownership but typically do not reflect broader industry trends.

Stakeholder Impact

• Shareholders: Provides transparency regarding executive compensation and ownership, confirming alignment of interests through equity awards.
• Employees: Reflects the company's equity compensation structure for executives.

Next Steps

• Remaining 34% of performance-based restricted stock units will vest on January 1, 2027.
• Remaining 67% of standard restricted stock units will vest in equal quarterly installments over a two-year period following October 1, 2025.

Key Dates

Keywords

Guardant Health, GH, SEC Form 4, Insider Trading, Stock Transaction, Restricted Stock Units, RSU Vesting, Employee Stock Purchase Plan, CPO, Terilyn J. Monroe, Beneficial Ownership